Loading...
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Butts, C Socinski, M Mitchell, Pa Thatcher, Nick Havel, L Krzakowski, M Nawrocki, S Ciuleanu, T Bosquée, L Trigo, J
Butts, C
Socinski, M
Mitchell, Pa
Thatcher, Nick
Havel, L
Krzakowski, M
Nawrocki, S
Ciuleanu, T
Bosquée, L
Trigo, J
Citations
Altmetric:
Abstract
Effective maintenance therapies after chemoradiotherapy for lung cancer are lacking. Our aim was to investigate whether the MUC1 antigen-specific cancer immunotherapy tecemotide improves survival in patients with stage III unresectable non-small-cell lung cancer when given as maintenance therapy after chemoradiation.
Affiliation
Description
Date
2014-01
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 553.96 KB
Keywords
Type
Article
Citation
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. 2014, 15 (1):59-68 Lancet Oncol